The early-stage clinical trial marks the first U.S. testing of Alveltamig, an immunotherapy designed to help the immune ...
Small cell lung cancer, or SCLC, is aggressive, lethal and particularly cruel because chemotherapy initially works so well. But within just a few months, SCLC becomes resistant to drugs and dashes ...
The study, published in British scientific journal Nature, suggests that the disease may begin in basal stem cells — ...
ZL-1310, targeting DLL3, shows early antitumor activity in extensive-stage SCLC, with 74% of patients experiencing tumor shrinkage or disappearance. The FDA's fast track designation for ZL-1310 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback